Multi-omics integration and in vitro validation identify IL4R, IMPA2, and PRR4 as key therapeutic targets in chronic rhinosinusitis with nasal polyps - Top-Institutions - MDSpire

Multi-omics integration and in vitro validation identify IL4R, IMPA2, and PRR4 as key therapeutic targets in chronic rhinosinusitis with nasal polyps

  • By

  • Bo Wei

  • Weigang Gan

  • Jiaxin Li

  • Feng Wang

  • Jun Wang

  • Binbin Wang

  • Jiaoyu He

  • Feng Liu

  • June 15, 2026

  • 0 min

Share

Top Institutions in Otolaryngology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, Maryland

    Key Differentiators

    • Otolaryngology

  • #2

    University of Pennsylvania, Perelman School of Medicine
    University of Pennsylvania, Perelman School of Medicine

    Philadelphia, Pennsylvania

    Key Differentiators

    • Otolaryngology

  • #3

    American University of Beirut Medical Center
    American University of Beirut Medical Center

    Beirut, Lebanon

    Key Differentiators

    • Otolaryngology

Original Source(s)

Multi-omics integration and in vitro validation identify IL4R, IMPA2, and PRR4 as key therapeutic targets in chronic rhinosinusitis with nasal polyps

  • by Bo Wei, Weigang Gan, Jiaxin Li, Feng Wang, Jun Wang, Binbin Wang, Jiaoyu He, Feng Liu

  • June 15, 2026

Related Content

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.